Stephen ClarkeVice President and Head of Drug Metabolism and Pharmacokinetics GlaxoSmithKline
Tom BaillieDean, School of Pharmacy University of Washington
Kaushik MitraDirector Merck
Griff HumphreysExecutive Director Bristol-Myers Squibb
With financial stakes of R&D soaring, and idiosyncratic adverse drug reactions becoming the most common cause for drug withdrawal, it has never been more crucial to make the right decisions to reduce the attrition of your pipeline.
The 2nd Mitigation Strategies for Reactive Metabolites is the only meeting dedicated to helping you implement more effective risk assessment strategies for reactive metabolites in your organization and truly minimize the attrition of your pipeline.
2nd Mitigation Strategies for Reactive Metabolites will tap into the latest industry case studies to ensure you are up to date with the latest advances in pharma strategies. Join in discussions with some of the leaders in the field to develop industry consensuses in risk mitigation strategies.
“Provides an excellent cross-pharma discussion on the issues and strategies for addressing reactive metabolites”
Hear the most recent developments in the field which are discussed nowhere else and join the discussions to define industry best practice for preclinical risk assessments in drug development. Ensure patient safety in clinical trials and prevent the loss of drug candidates from iADRs.
Not only will companies like Pfizer, Merck, Roche, Bristol-Myers Squibb, GSK and Amgen be sharing their preclinical risk assessment strategies but topics will cover all of the latest advances in this field including:
With the leaders in the field all in one room, you will leave with the knowledge to:
For more information about what will be covered, please download the brochure now.
This meeting will ensure you are equipped with all the knowledge you need to put effective strategies in place to mitigate against reactive metabolites and prevent the loss of promising candidates from IADRs.
2nd Mitigation Strategies for Reactive Metabolites is the world’s only annual meeting dedicated to managing the risk of reactive metabolites in drug discovery and development. That means the meeting is for:
“Provides an excellent cross-pharma discussion on the issues and strategies for addressing reactive metabolites” GSK
"Excellent, thorough review of topics" Pfizer
"Focused and yet comprehensive reviews on RM & IDFR issues and strategies" AstraZeneca
“Truly enjoyed listening to the industry experts. Very interesting case studies presented” Idenix
“Topic and speakers are very good, up to date capture of the key issues we are facing in Drug Dx & Dr” AstraZeneca
"Nice line up of speakers and stimulating presentations. This is an important and timely topic to have a dedicated conference for." Merck